000963 华东医药
已收盘 05-08 15:00:00
资讯
新帖
简况
华东医药：医美业务经营业绩已完整、准确地体现在公司财务报表中
证券之星 · 05-08 16:06
华东医药：医美业务经营业绩已完整、准确地体现在公司财务报表中
华东医药：HDM3001克罗恩病适应症预计2026年Q2获批
证券之星 · 05-08 15:51
华东医药：HDM3001克罗恩病适应症预计2026年Q2获批
华东医药：HDM1005的MASH适应症已获得中国和美国IND批准
证券之星 · 05-08 15:45
华东医药：HDM1005的MASH适应症已获得中国和美国IND批准
华东医药：公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期
证券之星 · 04-29
华东医药：公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期
【机构调研记录】东海基金调研理邦仪器、华东医药等4只个股（附名单）
证券之星 · 04-28
【机构调研记录】东海基金调研理邦仪器、华东医药等4只个股（附名单）
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
华东医药（000963）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-25
华东医药（000963）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
国金证券：给予华东医药买入评级
证券之星 · 04-24
国金证券：给予华东医药买入评级
华东医药最新公告：第一季度净利润同比增长9.56%
证券之星 · 04-23
华东医药最新公告：第一季度净利润同比增长9.56%
华东医药最新公告：全资子公司伊妍仕M型获医疗器械注册证
证券之星 · 04-23
华东医药最新公告：全资子公司伊妍仕M型获医疗器械注册证
华东医药最新公告：独家商业化产品CXG87上市许可申请获受理
证券之星 · 04-22
华东医药最新公告：独家商业化产品CXG87上市许可申请获受理
华东医药最新公告：全资子公司司美格鲁肽注射液上市申请获受理
证券之星 · 04-14
华东医药最新公告：全资子公司司美格鲁肽注射液上市申请获受理
股市必读：华东医药（000963）4月3日董秘有最新回复
证券之星 · 04-07
股市必读：华东医药（000963）4月3日董秘有最新回复
华东医药最新公告：注射用重组A型肉毒毒素获批上市
证券之星 · 03-27
华东医药最新公告：注射用重组A型肉毒毒素获批上市
华东医药（000963）披露全资子公司获得药物临床试验批准通知书，3月26日股价下跌1.93%
证券之星 · 03-26
华东医药（000963）披露全资子公司获得药物临床试验批准通知书，3月26日股价下跌1.93%
华东医药(000963.SZ)：注射用HDM2024临床试验申请获批准
智通财经 · 03-26
华东医药(000963.SZ)：注射用HDM2024临床试验申请获批准
华东医药（000963）披露控股股东部分股份质押及解除质押公告，3月20日股价下跌1.88%
证券之星 · 03-20
华东医药（000963）披露控股股东部分股份质押及解除质押公告，3月20日股价下跌1.88%
华东医药（000963）披露全资子公司获得美国FDA新药临床试验批准通知，3月11日股价下跌0.14%
证券之星 · 03-11
华东医药（000963）披露全资子公司获得美国FDA新药临床试验批准通知，3月11日股价下跌0.14%
华东医药(000963.SZ)：注射用HDM2024药品临床试验申请已获得美国FDA批准
智通财经 · 03-11
华东医药(000963.SZ)：注射用HDM2024药品临床试验申请已获得美国FDA批准
顶尖药企竞相推出减重口服药
环球市场播报 · 03-06
顶尖药企竞相推出减重口服药
暂无数据
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":33.26,"timestamp":1778223801000,"preClose":33.3,"halted":0,"volume":6667074,"delay":0,"changeRate":-0.0012,"floatShares":1753000000,"shares":1754000000,"eps":1.9968,"marketStatus":"已收盘","change":-0.04,"latestTime":"05-08 15:00:00","open":33.31,"high":33.36,"low":33.19,"amount":222000000,"amplitude":0.0051,"askPrice":33.26,"askSize":20,"bidPrice":33.25,"bidSize":678,"shortable":0,"etf":0,"ttmEps":1.9968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":5,"adr":0,"adjPreClose":33.3,"symbolType":"stock","openAndCloseTimeList":[[1778203800000,1778211000000],[1778216400000,1778223600000]],"highLimit":36.63,"lowLimit":29.97,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":2.27,"roa":"--","peRate":16.656651,"roe":"3.97%","epsLYR":1.9484,"committee":0.405194,"marketValue":58329000000,"turnoverRate":0.0038,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-11。","floatMarketCap":58305000000},"requestUrl":"/m/hq/s/000963/tweets","defaultTab":"tweets","newsList":[{"id":"2633433995","title":"华东医药：医美业务经营业绩已完整、准确地体现在公司财务报表中","url":"https://stock-news.laohu8.com/highlight/detail?id=2633433995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633433995?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:06","pubTimestamp":1778227567,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月08日在投资者关系平台上答复投资者关心的问题。让估值起来促进华东品牌效应也会促进下阶段医美产品销售！谢谢华东医药回复：您好！公司始终严格遵守法律法规及企业会计准则，所有年度财务数据均经独立审计并依法披露。医美业务作为公司重要业务板块之一，其经营业绩已完整、准确地体现在公司财务报表中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800026972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0175","BK0183","LU2328871848.SGD","BK0196","BK0187","BK0209","BK0132","LU1969619763.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633438740","title":"华东医药：HDM3001克罗恩病适应症预计2026年Q2获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2633438740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633438740?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:51","pubTimestamp":1778226669,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否有相关治疗克罗恩病的药物?在这方面后续还有没有新药推出?华东医药回复：您好！公司与荃信生物合作的乌司奴单抗生物类似药HDM3001（QX001S）克罗恩病适应症的注册申请预计将于2026年Q2获批。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800024616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0188","BK0209","LU2328871848.SGD","BK0196","BK0183","LU1969619763.USD","BK0187","000963","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633901438","title":"华东医药：HDM1005的MASH适应症已获得中国和美国IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2633901438","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633901438?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:45","pubTimestamp":1778226312,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在mash领域，除了dr10624，还有哪些布局吗华东医药回复：您好！在MASH治疗领域，公司另一款GLP-1/GIP双靶点长效激动剂HDM1005的MASH适应症已获得中国和美国IND批准。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800023627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","LU2328871848.SGD","LU1969619763.USD","BK0187","BK0183","000963","BK0175","BK0196","BK0188","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631355374","title":"华东医药：公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2631355374","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631355374?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:48","pubTimestamp":1777423716,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药04月28日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司从19年就开始创新转型，从25年有所起色！公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期。近年来，我们通过自主研发与对外合作双轮驱动，已引入多款具有竞争力的产品，研发效率与质量均在稳步提升。未来，公司将继续聚焦差异化创新，推动公司可持续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900027305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0188","BK0175","BK0132","LU2328871848.SGD","000963","LU1969619763.USD","BK0196","BK0209","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630349714","title":"【机构调研记录】东海基金调研理邦仪器、华东医药等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2630349714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630349714?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:04","pubTimestamp":1777334666,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月27日披露的机构调研信息，东海基金近期对4家上市公司进行了调研，相关名单如下：1）理邦仪器 调研纪要：2026年一季度公司实现营业收入5.16亿元，同比增长22.82%；归母净利润达1.05亿元，同比增长61.39%。2）华东医药 调研纪要：今年一季度，创新产品对公司收入的贡献持续攀升，当期实现销售及代理服务收入合计8.1亿元，同比增幅达61.8%，占医药工业营业收入比重为20.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800026566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0175","BK0251","BK0187","300206","BK0209","BK0183","LU1969619763.USD","BK0132","BK0196","BK0146","000963","LU2328871848.SGD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0071","BK0183","BK0216","301281","BK0250","000963","BK0132","688117","BK0191","BK0188","300723","600216","BK1574","06978","LU2328871848.SGD","688621","BK0209","BK0196","BK0028","BK1161","000950","LU1969619763.USD","BK0239","BK0175","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630873825","title":"华东医药（000963）2026年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2630873825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630873825?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:21","pubTimestamp":1777069291,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期华东医药发布2026年一季报。截至本报告期末，公司营业总收入111.83亿元，同比上升4.17%，归母净利润10.02亿元，同比上升9.56%。本报告期华东医药盈利能力上升，毛利率同比增幅3.25%，净利率同比增幅4.73%。本次财报公布的各项数据指标表现尚佳。去年的净利率为7.82%，算上全部成本后，公司产品或服务的附加值一般。持有华东医药最多的基金为创新药ETF银华，目前规模为151.77亿元，最新净值0.8291，较上一交易日下跌1.09%，近一年上涨14.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500020551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629986792","title":"国金证券：给予华东医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629986792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629986792?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:37","pubTimestamp":1776991050,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,马居东近期对华东医药进行研究并发布了研究报告《医药工业增长稳健，创新成果逐步兑现》，给予华东医药买入评级。维持“买入”评级 风险提示 研发进度不及预期的风险；商业化进度不及预期的风险；技术成果无法有效转化风险。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为54.05。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400024490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629042853","title":"华东医药最新公告：第一季度净利润同比增长9.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629042853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629042853?lang=zh_cn&edition=full","pubTime":"2026-04-23 23:00","pubTimestamp":1776956444,"startTime":"0","endTime":"0","summary":"华东医药公告称，2026年第一季度实现营业收入111.83亿元，同比增长4.17%；归属于上市公司股东的净利润为10.02亿元，同比增长9.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300063282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629483145","title":"华东医药最新公告：全资子公司伊妍仕M型获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2629483145","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629483145?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:31","pubTimestamp":1776947476,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司欣可丽美学(杭州)供应链管理有限公司收到国家药监局签发的《医疗器械注册证》，其代理申报的三类医疗器械注射用聚己内酯微球面部填充剂Ellansé伊妍仕M型(商品名：伊妍仕恒耀TM)注册申请获得上市批准。该产品适用于改善成人轻中度颞部凹陷。此次获批将进一步夯实并扩容公司高端再生医美产品管线，完善高端注射医美产品矩阵，对公司医美业务有积极影响，但不会对公司当前财务状况和经营成果产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300058247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","159883","09997","BK1574","BK0187","09996","LU2328871848.SGD","BK0209","BK0132","BK0175","BK0196","BK0188","BK1583","000963","LU1969619763.USD","BK0183","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629016231","title":"华东医药最新公告：独家商业化产品CXG87上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2629016231","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629016231?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:59","pubTimestamp":1776848393,"startTime":"0","endTime":"0","summary":"华东医药公告称，公司全资子公司华东医药(杭州)独家商业化产品CXG87的药品注册上市许可申请获国家药监局受理。CXG87为2.2类改良型新药，用于治疗哮喘。此前公司与畅溪制药达成合作，由畅溪制药负责研发生产，公司负责中国大陆地区独家商业化推广。本次申请获受理对公司当期业绩无重大影响，长期有利于提升核心竞争力。后续审批结果及市场情况存在不确定性，敬请投资者注意风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200038752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0209","LU2328871848.SGD","LU1969619763.USD","BK0187","000963","BK0183","BK0175","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441796","title":"华东医药最新公告：全资子公司司美格鲁肽注射液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441796","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627441796?lang=zh_cn&edition=full","pubTime":"2026-04-14 18:31","pubTimestamp":1776162678,"startTime":"0","endTime":"0","summary":"华东医药公告称，公司全资子公司杭州中美华东制药江东有限公司收到国家药监局签发的《受理通知书》，其申报的司美格鲁肽注射液用于成人患者长期体重管理的上市许可申请获得受理。截至目前，公司在该项目的研发直接投入总金额约为8551万元。本次申请获受理是产品研发的重要里程碑，有助于提升公司在内分泌治疗领域的核心竞争力。鉴于药品审评审批时间及结果存在不确定性，敬请投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400031020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","LU1969619763.USD","BK0187","LU2328871848.SGD","BK0188","BK0209","000963","BK0196","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625601574","title":"股市必读：华东医药（000963）4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625601574?lang=zh_cn&edition=full","pubTime":"2026-04-07 04:23","pubTimestamp":1775506989,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，华东医药报收于36.29元，下跌1.6%，换手率0.66%，成交量11.54万手，成交额4.19亿元。董秘最新回复投资者： 尊敬的董秘，您好！公司独家经销产品芮妥欣正按计划积极推进上市销售准备工作。具体产品的研发进展，您可查阅公司以往或后续发布的定期报告。交易信息汇总资金流向4月3日主力资金净流出153.37万元，占总成交额0.37%；游资资金净流出2498.19万元，占总成交额5.97%；散户资金净流入2651.56万元，占总成交额6.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","LU1969619763.USD","LU2328871848.SGD","000963","BK0187","BK0188","BK0183","BK0175","BK0132","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622265828","title":"华东医药最新公告：注射用重组A型肉毒毒素获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2622265828","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622265828?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:39","pubTimestamp":1774607999,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司独家经销产品注射用重组A型肉毒毒素(商品名：芮妥欣)获得国家药监局批准上市，用于改善65岁及以下成人中重度眉间纹。该产品由重庆誉颜制药有限公司研发，为全球首款重组A型肉毒毒素，具有纯度高、比活性高、免疫原性低等优势。公司拥有其在中国大陆及港澳地区医美适应症的独家商业化权益。该产品获批将进一步完善公司医美高端注射产品矩阵，实现肉毒毒素、玻尿酸及高端再生产品的全覆盖，但短期内不会对公司财务状况产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700040791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","LU2328871848.SGD","BK0196","LU1969619763.USD","BK0209","BK0183","000963","BK0188","BK0187","BK0175","150259"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622086693","title":"华东医药（000963）披露全资子公司获得药物临床试验批准通知书，3月26日股价下跌1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622086693","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622086693?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:12","pubTimestamp":1774534341,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，华东医药报收于33.5元，较前一交易日下跌1.93%，最新总市值为587.5亿元。近日，华东医药披露公告显示，2026年3月25日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意其申报的注射用HDM2024开展晚期实体瘤的临床试验。该药此前已获美国FDA批准开展I期临床试验。本次获批对公司近期业绩无重大影响，后续仍需进行临床试验及审评审批。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0175","BK0132","BK0183","BK0196","LU1969619763.USD","BK0188","LU2328871848.SGD","000963","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622853653","title":"华东医药(000963.SZ)：注射用HDM2024临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622853653","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622853653?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:31","pubTimestamp":1774517505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药(000963.SZ)公告，公司全资子公司杭州中美华东制药有限公司(简称“中美华东”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由中美华东申报的注射用HDM2024临床试验申请获得批准，同意开展晚期实体瘤的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华东医药(000963.SZ)：注射用HDM2024临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0188","BK0175","000963","BK0132","BK0196","LU2328871848.SGD","BK0209","LU1969619763.USD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620781450","title":"华东医药（000963）披露控股股东部分股份质押及解除质押公告，3月20日股价下跌1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620781450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620781450?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:18","pubTimestamp":1773998336,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，华东医药报收于34.97元，较前一交易日下跌1.88%，最新总市值为613.28亿元。该股当日开盘35.6元，最高35.82元，最低34.8元，成交额达3.01亿元，换手率为0.49%。公告显示，公司接到控股股东中国远大集团有限责任公司通知，远大集团将其持有的公司部分股份办理了质押及解除质押。同时，解除质押6,180,000股，占其所持股份比例0.85%，占公司总股本比例0.35%。公司表示，本次质押变动不存在平仓风险，不会对公司生产经营和公司治理产生影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000029953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0183","BK0209","BK0132","LU1969619763.USD","BK0196","BK0187","LU2328871848.SGD","BK0188","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618318925","title":"华东医药（000963）披露全资子公司获得美国FDA新药临床试验批准通知，3月11日股价下跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618318925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618318925?lang=zh_cn&edition=full","pubTime":"2026-03-11 22:21","pubTimestamp":1773238876,"startTime":"0","endTime":"0","summary":"截至2026年3月11日收盘，华东医药报收于35.37元，较前一交易日下跌0.14%，最新总市值为620.3亿元。近日，华东医药披露公告显示，其全资子公司杭州中美华东制药有限公司于2026年3月10日收到美国FDA通知，其申报的注射用HDM2024临床试验申请已获批准，可在美开展I期临床试验，适应症为晚期实体瘤。该药已于2026年1月在中国提交临床试验申请，目前处于审评阶段。此次获批对公司近期业绩无重大影响，后续仍需开展多项临床试验并经审批方可上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100039476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0209","LU2328871848.SGD","BK0183","BK0187","LU1969619763.USD","BK0188","BK0196","BK0132","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618944821","title":"华东医药(000963.SZ)：注射用HDM2024药品临床试验申请已获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944821","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618944821?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:42","pubTimestamp":1773229341,"startTime":"0","endTime":"0","summary":"HDM2024 由靶向EGFR/HER3 的双抗分子，可裂解的连接子及DNA拓扑异构酶1抑制剂细胞毒性分子组成。HDM2024 可同时阻断EGFR/HER3信号通路，能够有效的阻断肿瘤细胞增殖信号，同时向肿瘤细胞内释放毒素载荷，发挥肿瘤杀伤作用。临床前研究已证明HDM2024在靶点不同表达水平的多种实体瘤药效模型中显示出强大的抗肿瘤活性，具有良好的成药性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK0196","BK0183","BK0132","LU1969619763.USD","BK0188","LU2328871848.SGD","000963","BK0175","BK4588","BK4585","BK0209","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617635561","title":"顶尖药企竞相推出减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:16","pubTimestamp":1772806560,"startTime":"0","endTime":"0","summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。 这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。 诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。 中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2097828714.EUR","LU2488822045.USD","LU0868494617.USD","IE00BLSP4452.SGD","LU0289739699.SGD","LU0122379950.USD","LU1023059063.AUD","SG9999002224.SGD","SG9999001176.USD","LU2097828631.EUR","BK4581","BK4588","LU0306806265.USD","LU1969619763.USD","SG9999001176.SGD","LU1057294990.SGD","LU2097828474.EUR","LLY","LU0985481810.HKD","LU1066051498.USD","PFE","LU0225284248.USD","LU1066053197.SGD","LU2097828557.USD","000963","VKTX","IE0002270589.USD","LU2242644610.SGD","RHHBY","IE00BBT3K403.USD","AZN","01801","BK4007","LU0455707207.USD","LU0170899867.USD","LU0306807586.USD","SG9999003800.SGD","LU1894683348.USD","LU0321505439.SGD","LU0058720904.USD","LU2328871848.SGD","IE00B19Z3581.USD","LU0234572021.USD","SG9999011175.SGD","BK4592","SG9999002232.USD","LU0321505868.SGD","BK4568","BK4585","HK0000165453.HKD","LU1883839398.USD","SGXZ57979304.SGD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU0225771236.USD","NVO","BK4533","IE000M9KFDE8.USD","BK1589","LU0456855351.SGD","LU0502904849.HKD","LU1894683264.USD","LU2097828805.USD","MRK","SG9999013999.USD","BK1583","BK4550","BK1161","BK4599","BK4534"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"ret":0,"serverTime":1778394066547,"stockEarnings":[{"period":"1week","weight":-0.0027},{"period":"1month","weight":-0.0825},{"period":"3month","weight":-0.0863},{"period":"6month","weight":-0.1747},{"period":"1year","weight":-0.1294},{"period":"ytd","weight":-0.1569}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"84304人(较上一季度增加26.48%)","perCapita":"20793股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}